Drug maker Gilead (GILD) is rallying 7.5% after the company reported stronger-than-expected fourth-quarter results and provided 2025 earnings per share guidance that came in above analysts ...

Shares of biopharmaceutical company Gilead Sciences (NASDAQ:GILD) jumped 8.6% in the morning session after the company reported impressive fourth-quarter results that exceeded analysts' revenue ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price target of $115.00. The company’s shares closed ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $110.00. The company’s shares closed yesterday at $96.14.

In early trading on Wednesday, shares of Gilead Sciences topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.0%. Year to date, Gilead Sciences registers a ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

GILD's steady cash flows and low volatility make it suitable for capturing covered call/put premiums during mispricing opportunities, rather than a long-only strategy. There's a lot of uncertainty ...

Good afternoon, everyone, and welcome to Gilead's Fourth Quarter and Full Year 2024 Earnings Conference Call. My name is Rebecca, and I'll be today's host. In a moment, we'll begin our prepared ...

GILD is a #3 (Hold) on the Zacks Rank, with a VGM Score of A. It also boasts a Value Style Score of B thanks to attractive valuation metrics like a forward P/E ratio of 12.67; value investors ...

Commissions do not affect our editors' opinions or evaluations. The price of gold today, as of 9:12 am ET, was $2,910.10 per ounce. That’s up 0.42% from yesterday’s gold price of $2,897.93.

The Foster City-based company (Nasdaq: GILD) said it earned $480 million in 2024 on sales within its portfolio of HIV, inflammation and cancer drugs that grew 6% year-over-year to $28.6 billion.